Cevimeline
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Cevimeline
|
|
| Systematic (IUPAC) name | |
| 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C10H17NOS |
| Mol. mass | 489.565 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | < 20% |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status |
Rx only |
| Routes | Oral |
Cevimeline is a parasympathomimetic and muscarinic agonist, with particular effect on M3 receptors. It is used in the treatment of dry mouth associated with Sjögren's syndrome.
Contents |
[edit] Mechanism of action
By activating the M3 receptors of the parasympathetic nervous system, cevimeline stimulates secretion by the salivary glands, thereby alleviating dry mouth.
[edit] Side effects
Known side effects include nausea, vomiting, diarrhea, excessive sweating, rash, headache, runny nose, cough, drowsiness, hot flashes, blurred vision, and difficulty sleeping. [1]
